marketcaparena
Search

    CPIX

    CUMBERLAND PHARMACEUTICALS INC

    Company overview

    Market capitalization
    $115.67M
    Employees
    93
    Latest publication
    2026-09-29
    About CUMBERLAND PHARMACEUTICALS INC

    Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ2 20232023-06-30 · USDQ3 20222022-09-30 · USDQ1 20212021-03-31 · USDQ4 20192019-12-31 · USDQ2 20192019-06-30 · USD
    Total Revenue8,292,362USD10,837,363USD11,713,055USD10,888,877USD11,413,072USD10,537,159USD13,678,372USD11,580,600USD
    Cost Of Revenue988,760USD2,011,389USD1,425,714USD1,520,774USD2,224,443USD2,417,329USD2,818,213USD2,012,196USD
    Gross Profit7,303,602USD8,825,974USD10,287,341USD9,368,103USD9,188,629USD8,119,830USD10,860,159USD9,568,404USD
    Research Development1,253,367USD1,468,399USD1,295,076USD1,145,038USD1,714,254USD1,257,367USD2,474,612USD1,458,366USD
    Selling General Administrative2,572,066USD2,874,922USD2,463,008USD2,369,883USD2,166,118USD2,230,509USD2,740,575USD2,528,916USD
    Selling And Marketing Expenses4,433,831USD4,223,647USD4,231,980USD4,672,075USD4,110,397USD3,787,340USD5,592,963USD5,153,129USD
    Unclassified Operating Expenses1,009,598USD1,006,484USD1,005,330USD1,158,248USD1,486,448USD1,168,914USD1,049,418USD1,029,708USD
    Total Operating Expenses9,268,862USD9,573,452USD8,995,394USD9,345,244USD9,477,217USD8,444,130USD11,857,568USD10,170,119USD
    Operating Income-1,965,260USD-747,478USD1,291,947USD22,859USD-288,588USD-324,300USD-997,409USD-601,715USD
    Interest Income131,583USD127,489USD125,709USD57,061USD21,602USD5,426USD47,449USD130,565USD
    Interest Expense109,699USD109,547USD163,802USD192,635USD149,340USD24,417USD29,198USD91,200USD
    Net Interest Income21,884USD17,942USD-38,093USD-135,574USD-127,738USD-18,991USD18,251USD39,365USD
    Income Before Tax-1,943,376USD-729,536USD1,253,854USD869,091USD-416,326USD-343,291USD-979,158USD-562,350USD
    Income Tax Expense5,670USD5,671USD5,670USD6,937USD6,900USD7,458USD-6,812USD4,462USD
    Tax Provision5,670USD5,671USD5,670USD6,937USD6,900USD7,458USD-6,812USD4,462USD
    Net Income-1,940,764USD-740,740USD1,257,068USD872,200USD-408,639USD166,828USD-960,706USD-549,507USD
    Net Income From Continuing Ops-1,949,046USD-735,207USD1,248,184USD862,154USD-423,226USD-350,749USD-975,234USD-584,117USD
    Ebit-1,833,677USD-619,989USD1,417,656USD1,061,726USD-266,986USD-318,874USD-949,960USD-471,151USD
    Ebitda-795,873USD699,114USD2,734,424USD2,558,791USD1,277,559USD908,733USD175,257USD627,000USD
    Depreciation And Amortization1,037,804USD1,319,103USD1,316,768USD1,497,065USD1,544,545USD1,227,607USD1,125,217USD1,098,151USD
    Reconciled Depreciation1,322,988USD1,319,103USD1,316,768USD1,200,915USD1,544,545USD1,227,607USD1,125,217USD1,098,151USD
    Total Other Income Expense Net21,884USD17,942USD-38,093USD846,232USD-127,738USD-18,991USD18,251USD811,074USD
    Minority Interest8,282USD-5,533USD8,884USD10,046USD14,587USD-22,167USD-11,640USD-17,305USD
    Net Income Applicable To Common Shares———872,200USD-408,639USD166,828USD-960,706USD-549,507USD
    Non Operating Income Net Other—————5,426USD47,449USD130,565USD
    Discontinued Operations—————495,410USD818,273USD818,273USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20152015-12-31 · USDFY 20142014-12-31 · USDFY 20122012-12-31 · USDFY 20112011-12-31 · USDFY 20102010-12-31 · USDFY 20092009-12-31 · USDFY 20082008-12-31 · USDFY 20072007-12-31 · USD
    Total Revenue33,519,051USD36,901,871USD48,851,237USD51,142,776USD45,876,371USD43,537,278USD35,075,160USD28,063,589USD
    Cost Of Revenue4,968,170USD5,053,165USD5,046,179USD5,362,554USD3,586,646USD4,136,541USD3,045,672USD2,669,628USD
    Gross Profit28,550,881USD31,848,706USD43,805,058USD45,780,222USD42,289,725USD39,400,737USD32,029,488USD25,393,961USD
    Research Development3,847,651USD3,389,419USD5,095,172USD5,028,072USD4,327,485USD4,993,278USD4,429,064USD3,693,917USD
    Selling General Administrative7,607,588USD8,401,560USD9,096,165USD9,197,955USD7,990,222USD7,643,070USD5,139,937USD4,137,942USD
    Selling And Marketing Expenses13,994,768USD14,902,202USD20,329,493USD20,940,060USD22,674,505USD20,194,074USD14,387,153USD10,053,355USD
    Unclassified Operating Expenses1,989,264USD1,596,689USD——————
    Total Operating Expenses27,439,271USD28,289,870USD34,986,956USD35,930,735USD35,787,978USD33,624,102USD24,747,267USD18,668,643USD
    Operating Income-1,111,610USD3,558,836USD8,818,102USD9,849,487USD6,501,747USD5,776,635USD7,282,221USD6,725,318USD
    Interest Income135,320USD———————
    Interest Expense73,856USD67,074USD71,985USD353,497USD1,423,523USD772,927USD213,303USD639,590USD
    Income Before Tax1,246,937USD3,743,209USD9,050,982USD9,706,717USD5,278,431USD5,083,071USD7,310,200USD6,468,647USD
    Income Tax Expense575,829USD1,380,744USD3,244,776USD4,080,204USD2,851,420USD2,024,192USD2,543,951USD2,424,261USD
    Tax Provision575,830USD———————
    Net Income731,351USD2,423,723USD5,842,492USD5,657,856USD2,456,680USD3,091,415USD4,766,249USD4,044,386USD
    Net Income From Continuing Ops671,108USD2,362,465USD5,806,206USD5,626,513USD————
    Ebit1,320,793USD3,743,213USD9,122,967USD9,960,214USD6,701,954USD5,855,998USD7,523,503USD7,108,237USD
    Ebitda3,567,602USD5,732,777USD10,024,616USD11,000,621USD7,680,352USD6,672,497USD8,310,100USD7,870,459USD
    Depreciation And Amortization2,246,809USD1,989,564USD901,649USD1,040,407USD978,398USD816,499USD786,597USD762,222USD
    Total Other Income Expense Net135,327USD184,373USD232,880USD-142,770USD-1,223,316USD-693,564USD27,979USD-256,671USD
    Non Operating Income Net Other209,183USD251,447USD304,865USD210,727USD————
    Minority Interest-60,243USD-61,258USD-36,286USD-31,343USD————
    Net Income Applicable To Common Shares731,351USD2,424,000USD5,842,492USD5,657,856USD2,457,000USD3,091,000USD4,766,000USD4,044,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets70,995,020USD76,823,992USD65,898,560USD67,907,149USD69,935,878USD75,583,410USD76,747,513USD78,519,175USD
    Intangible Assets12,793,249USD14,027,921USD15,010,795USD15,988,232USD16,986,962USD17,973,449USD19,415,232USD20,458,835USD
    Other Current Assets2,066,198USD2,445,276USD1,377,378USD1,578,265USD2,181,954USD2,786,513USD1,951,358USD2,322,725USD
    Total Liab49,692,008USD52,279,770USD40,097,856USD40,228,222USD41,595,259USD53,037,433USD52,278,121USD52,486,991USD
    Total Stockholder Equity21,636,524USD24,880,322USD26,119,854USD27,989,795USD28,657,020USD22,853,494USD24,779,086USD26,348,990USD
    Other Current Liab17,465,817USD17,709,599USD10,076,027USD10,139,532USD11,220,902USD12,250,955USD12,649,195USD11,871,363USD
    Common Stock51,730,222USD51,684,381USD51,512,221USD51,441,398USD51,367,883USD46,821,425USD46,843,203USD46,869,026USD
    Capital Stock51,730,222USD51,684,381USD51,512,221USD51,441,398USD51,367,883USD46,821,425USD46,843,203USD46,869,026USD
    Retained Earnings-30,093,698USD-26,804,059USD-25,392,367USD-23,451,603USD-22,710,863USD-23,967,931USD-22,064,117USD-20,520,036USD
    Good Will914,000USD914,000USD914,000USD914,000USD914,000USD914,000USD914,000USD914,000USD
    Cash11,007,245USD11,444,693USD15,196,745USD16,087,281USD15,108,413USD17,964,184USD17,464,754USD17,336,446USD
    Cash And Short Term Investments11,007,245USD11,444,693USD15,196,745USD16,087,281USD15,108,413USD17,964,184USD17,464,754USD17,336,446USD
    Total Current Assets32,789,257USD37,060,267USD29,939,448USD31,205,329USD31,877,151USD36,452,158USD35,236,406USD35,581,093USD
    Total Current Liabilities34,488,051USD36,744,919USD24,309,969USD23,972,140USD25,519,619USD31,621,729USD31,087,515USD24,756,169USD
    Net Debt-937,458USD-1,264,221USD-4,958,799USD-5,746,288USD-4,667,532USD2,608,233USD4,015,738USD4,232,186USD
    Short Term Debt485,162USD467,774USD401,445USD386,077USD371,094USD5,456,508USD6,380,608USD376,780USD
    Short Long Term Debt Total10,069,787USD10,180,472USD10,237,946USD10,340,993USD10,440,881USD20,572,417USD21,480,492USD21,568,632USD
    Long Term Debt5,240,733USD5,240,733USD5,240,733USD5,240,733USD5,240,733USD10,176,170USD10,102,672USD16,091,592USD
    Long Term Investments3,840,700USD3,986,780USD———0USD——
    Net Receivables14,261,978USD16,944,780USD10,430,602USD10,316,911USD10,487,925USD11,701,466USD11,310,625USD11,619,763USD
    Inventory5,453,836USD6,225,518USD2,934,723USD3,222,872USD4,098,859USD3,999,995USD4,509,669USD4,302,159USD
    Accounts Payable16,537,072USD18,567,546USD13,832,497USD13,446,531USD13,927,623USD13,914,266USD12,057,712USD12,508,026USD
    Property Plant Equipment Net7,856,095USD8,608,556USD7,863,827USD7,423,201USD7,476,230USD6,454,288USD6,520,442USD6,702,879USD
    Property Plant Equipment Gross7,856,095USD11,110,943USD7,863,827USD7,423,201USD7,476,230USD8,846,131USD6,520,442USD6,702,879USD
    Common Stock Shares Outstanding14,960,210shares14,956,627shares14,953,944shares14,960,596shares15,259,824shares13,971,228shares14,052,754shares14,118,091shares
    Non Current Assets Total38,205,763USD39,763,725USD35,959,112USD36,701,820USD38,058,727USD39,131,252USD41,511,107USD42,938,082USD
    Non Current Liabilities Total15,203,957USD15,534,850USD15,787,887USD16,256,082USD16,075,640USD21,415,704USD21,190,606USD27,730,822USD
    Non Current Liabilities Other5,619,332USD250,000USD5,951,386USD6,301,166USD6,005,853USD250,000USD6,090,722USD6,538,970USD
    Non Currrent Assets Other16,642,419USD12,226,468USD12,170,490USD12,376,387USD12,681,535USD13,789,515USD14,661,433USD14,862,368USD
    Net Working Capital-1,698,794USD315,348USD5,629,479USD7,233,189USD6,357,532USD4,830,429USD4,148,891USD10,824,924USD
    Unclassified Non Current Assets-3,840,700USD———————
    Unclassified Non Current Liabilities4,343,892USD10,044,117USD4,595,768USD4,714,183USD4,829,054USD10,989,534USD4,997,212USD5,100,260USD
    Unclassified Equity-51,730,222USD-51,684,381USD-51,512,221USD-51,441,398USD-51,367,883USD-46,821,425USD-46,843,203USD-46,869,026USD
    Short Long Term Debt—————5,100,000USD5,988,920USD—
    Unclassified Current Liabilities—————-5,100,000USD-5,988,920USD—
    Accumulated Other Comprehensive Income———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets76,823,992USD75,583,410USD81,776,075USD92,925,158USD84,459,798USD96,463,305USD104,549,283USD112,693,868USD
    Intangible Assets14,027,921USD17,973,449USD22,607,918USD30,590,678USD23,954,475USD28,118,316USD30,920,324USD33,655,099USD
    Other Current Assets2,445,276USD2,786,513USD3,025,248USD3,084,978USD3,339,969USD2,199,926USD5,220,180USD2,963,806USD
    Total Liab52,279,770USD53,037,433USD52,516,206USD56,951,152USD41,857,820USD49,589,911USD53,464,030USD57,123,367USD
    Total Stockholder Equity24,880,322USD22,853,494USD29,603,441USD36,266,132USD42,814,306USD46,990,510USD51,122,873USD55,844,767USD
    Other Current Liab17,709,599USD12,250,955USD13,596,528USD17,587,911USD8,668,303USD9,067,241USD13,236,226USD16,710,927USD
    Common Stock51,684,381USD46,821,425USD47,091,602USD47,474,973USD48,452,906USD49,121,523USD49,914,478USD51,098,613USD
    Capital Stock51,684,381USD46,821,425USD47,091,602USD47,474,973USD48,452,906USD49,121,523USD49,914,478USD51,098,613USD
    Retained Earnings-26,804,059USD-23,967,931USD-17,488,161USD-11,208,841USD-5,638,600USD-2,131,013USD1,208,395USD4,746,154USD
    Good Will914,000USD914,000USD914,000USD914,000USD882,000USD882,000USD882,000USD784,000USD
    Cash11,444,693USD17,964,184USD18,321,624USD19,757,970USD27,040,816USD24,753,796USD28,212,635USD27,938,960USD
    Cash And Short Term Investments11,444,693USD17,964,184USD18,321,624USD19,757,970USD27,040,816USD24,753,796USD28,212,635USD36,229,639USD
    Total Current Assets37,060,267USD36,452,158USD35,714,410USD45,870,210USD45,688,013USD49,969,592USD50,163,075USD74,865,037USD
    Total Current Liabilities36,744,919USD31,621,729USD27,982,249USD28,579,832USD19,278,960USD25,667,446USD24,150,235USD27,804,224USD
    Net Debt-1,264,221USD2,608,233USD106,859USD1,201,241USD-10,981,123USD-5,490,184USD-6,715,732USD-7,938,960USD
    Short Term Debt467,774USD5,456,508USD348,092USD172,910USD969,677USD3,203,919USD920,431USD—
    Short Long Term Debt Total10,180,472USD20,572,417USD18,428,483USD20,959,211USD16,059,693USD19,263,612USD21,496,903USD20,000,000USD
    Long Term Debt5,240,733USD10,176,170USD12,784,144USD16,200,000USD15,000,000USD15,000,000USD18,500,000USD20,000,000USD
    Long Term Investments3,986,780USD0USD——————
    Net Receivables16,944,780USD11,701,466USD9,758,176USD13,163,681USD6,877,346USD12,377,713USD7,859,006USD7,844,249USD
    Inventory6,225,518USD3,999,995USD4,609,362USD9,863,581USD8,429,882USD10,638,157USD8,871,254USD27,827,343USD
    Accounts Payable18,567,546USD13,914,266USD14,037,629USD10,819,011USD9,640,980USD13,396,286USD9,993,578USD11,093,297USD
    Property Plant Equipment Net8,608,556USD6,454,288USD7,042,297USD5,502,442USD1,466,835USD2,602,317USD3,708,365USD771,213USD
    Property Plant Equipment Gross11,110,943USD8,846,131USD9,280,370USD5,502,442USD1,466,835USD2,602,317USD3,708,365USD771,213USD
    Common Stock Shares Outstanding14,956,627shares14,060,272shares14,298,774shares14,563,592shares14,904,834shares15,162,184shares15,396,098shares15,614,052shares
    Non Current Assets Total39,763,725USD39,131,252USD46,061,665USD47,054,948USD38,771,785USD46,493,713USD54,386,208USD37,828,831USD
    Non Current Liabilities Total15,534,850USD21,415,704USD24,533,957USD28,371,320USD22,578,860USD23,922,465USD29,313,795USD29,319,143USD
    Non Current Liabilities Other250,000USD250,000USD274,000USD7,585,019USD224,786USD8,922,465USD10,813,795USD9,319,143USD
    Non Currrent Assets Other12,226,468USD13,789,515USD15,497,450USD10,047,828USD12,468,475USD14,891,080USD18,853,717USD2,531,309USD
    Net Working Capital315,348USD4,830,429USD7,732,161USD17,290,378USD26,409,053USD24,302,146USD26,012,840USD31,311,813USD
    Unclassified Non Current Liabilities10,044,117USD10,989,534USD11,475,813USD-2,998,718USD—-7,862,772USD-8,737,323USD-9,319,143USD
    Unclassified Equity-51,684,381USD-46,821,425USD-47,091,602USD-47,474,973USD-48,452,906USD-49,121,523USD-49,914,478USD-51,098,613USD
    Other Assets—75,583,334,416,590USD—10,047,828USD12,468,475USD17,801,228USD18,875,519USD18,367,519USD
    Short Long Term Debt—5,100,000USD———2,187,140USD——
    Unclassified Non Current Assets—-75,583,334,416,590USD—-10,047,828USD-12,468,475USD-17,801,228USD-18,853,717USD-18,280,309USD
    Unclassified Current Liabilities—-5,100,000USD———-2,187,140USD-5,499,728USD—
    Other Liab———7,585,019USD7,488,844USD7,862,772USD8,737,323USD9,319,143USD
    Net Tangible Assets———4,761,454USD17,977,831USD17,990,194USD19,320,549USD21,405,668USD
    Accumulated Other Comprehensive Income————0USD0USD0USD0USD
    Current Deferred Revenue——————5,499,728USD—
    Short Term Investments——————0USD8,290,679USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-3,287,051USD-1,428,642USD-1,949,046USD-740,740USD1,248,184USD-1,901,637USD-1,536,969USD-1,102,637USD
    Depreciation1,561,467USD1,327,079USD1,322,988USD1,319,103USD1,316,768USD1,781,579USD1,401,220USD1,424,630USD
    Stock Based Compensation106,842USD172,160USD81,262USD80,686USD74,212USD74,812USD76,371USD71,958USD
    Other Non Cash Items9,237USD-37,299USD-76,447USD-1,491,075USD131,520USD-475,668USD-1,928,323USD-179,368USD
    Change To Account Receivables2,682,802USD-6,514,178USD-113,691USD171,014USD1,213,541USD-390,841USD309,138USD-795,177USD
    Change To Inventory703,861USD-205,989USD630,409USD850,797USD967,399USD1,336,102USD-170,950USD1,072,776USD
    Change In Working Capital1,996,530USD-30,274USD808,423USD1,675,827USD1,127,833USD2,425,532USD2,463,204USD-1,070,243USD
    Total Cash From Operating Activities387,025USD3,024USD187,180USD843,801USD3,898,517USD1,904,618USD475,503USD-855,660USD
    Capital Expenditures-5USD-43,841USD-32,237USD-26,486USD-47,630USD-26,809USD-40,812USD-46,804USD
    Free Cash Flow387,025USD-40,817USD154,943USD817,315USD3,850,887USD1,877,809USD516,315USD-902,464USD
    Total Cashflows From Investing Activities-61,173USD-3,073,338USD-690,837USD285,864USD-1,228,186USD-26,809USD189,641USD-46,804USD
    Net Borrowings0USD0USD0USD0USD-10,035,437USD-815,422USD0USD—
    Total Cash From Financing Activities-763,300USD-681,738USD-386,879USD-150,797USD-5,526,102USD-1,378,379USD-536,836USD-309,575USD
    Sale Purchase Of Stock-61,000USD263,478USD-10,439USD-7,171USD-245,868USD-98,383USD-98,815USD-134,246USD
    Issuance Of Capital Stock0USD0USD0USD0USD5,266,334USD—0USD0USD
    Change In Cash-437,448USD-3,752,052USD-890,536USD978,868USD-2,855,771USD499,430USD128,308USD-1,212,039USD
    Begin Period Cash Flow11,444,693USD15,196,745USD16,087,281USD15,108,413USD17,964,184USD17,464,754USD17,336,446USD18,548,485USD
    End Period Cash Flow11,007,245USD11,444,693USD15,196,745USD16,087,281USD15,108,413USD17,964,184USD17,464,754USD17,336,446USD
    Other Cashflows From Investing Activities-42,018USD-43,842USD-55,449USD312,350USD-1,180,556USD-24,526USD148,829USD-39,626USD
    Other Cashflows From Financing Activities-702,300USD-5,948,072USD-376,440USD-143,626USD4,755,203USD-464,574USD-438,021USD-182,777USD
    Investments—-3,029,497USD-690,837USD285,864USD-1,228,186USD-26,809USD189,641USD-46,804USD
    Unclassified Financing Cash Flow—5,002,856USD——————
    Unclassified Investing Cash Flow————1,228,186USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-2,864,711USD-6,479,770USD-6,279,320USD-5,650,039USD-3,602,799USD-3,418,904USD-3,537,759USD-7,038,772USD
    Depreciation5,285,939USD6,043,298USD5,770,454USD5,328,113USD4,606,366USD4,748,565USD4,404,175USD2,982,703USD
    Stock Based Compensation408,320USD301,895USD365,040USD447,503USD741,867USD1,046,516USD1,485,898USD1,364,698USD
    Other Non Cash Items-59,953USD-1,770,787USD1,602,799USD-2,644,330USD-3,390,226USD-515,719USD2,341,898USD-150,443USD
    Change To Account Receivables-5,243,314USD-1,943,290USD3,404,949USD-6,115,640USD5,500,367USD-4,518,707USD-1,399,012USD550,863USD
    Change To Inventory2,242,616USD2,408,397USD-23,143USD1,375,078USD4,816,450USD2,131,347USD1,106,175USD460,505USD
    Change In Working Capital2,162,927USD1,293,178USD4,634,848USD10,972,149USD8,180,053USD3,532,801USD-1,637,856USD5,872,665USD
    Total Cash From Operating Activities4,932,522USD-612,186USD6,093,821USD8,453,396USD6,342,443USD5,415,061USD3,056,356USD3,112,737USD
    Capital Expenditures-97,902USD-179,714USD-453,051USD-2,073,810USD-354,462USD-2,113,927USD-246,202USD-4,275,055USD
    Free Cash Flow4,834,620USD-791,900USD5,640,770USD6,379,586USD5,987,981USD3,301,134USD2,810,154USD-1,162,318USD
    Investments-4,477,192USD57,842USD-1,007,106USD-13,674,456USD-501,893USD-1,757,789USD8,316,994USD-3,449,763USD
    Total Cashflows From Investing Activities-4,706,497USD57,842USD-105,695USD-13,674,456USD-501,893USD-1,757,789USD2,297,848USD-27,724,818USD
    Net Borrowings-10,035,437USD2,492,026USD-3,415,856USD1,200,000USD1,200,000USD-3,510,000USD-1,552,500USD10,200,000USD
    Total Cash From Financing Activities-6,745,516USD196,904USD-7,424,472USD-2,061,786USD-3,553,530USD-7,116,111USD-5,080,529USD7,138,173USD
    Sale Purchase Of Stock-263,478USD-579,049USD-740,533USD-1,053,042USD-1,386,849USD-1,851,526USD-3,494,921USD-2,879,426USD
    Issuance Of Capital Stock5,266,334USD0USD———0USD0USD200,909USD
    Change In Cash-6,519,491USD-357,440USD-1,436,346USD-7,282,846USD2,287,020USD-3,458,839USD273,675USD-17,473,908USD
    Begin Period Cash Flow17,964,184USD18,321,624USD19,757,970USD27,040,816USD24,753,796USD28,212,635USD27,938,960USD45,412,868USD
    End Period Cash Flow11,444,693USD17,964,184USD18,321,624USD19,757,970USD27,040,816USD24,753,796USD28,212,635USD27,938,960USD
    Other Cashflows From Investing Activities-47,000USD237,556USD347,356USD1,899,354USD52,569USD356,138USD7,544,050USD-7,269,249USD
    Other Cashflows From Financing Activities-1,712,935USD-1,716,073USD-3,268,083USD-2,208,744USD-2,166,681USD-1,764,585USD-85,608USD-383,310USD
    Unclassified Financing Cash Flow5,266,334USD———-1,200,000USD——56,200,909USD
    Unclassified Investing Cash Flow——1,007,106USD——1,757,789USD-13,316,994USD-12,730,751USD
    Change To Liabilities———14,536,076USD-757,591USD6,569,002USD1,094,204USD4,149,148USD
    Dividends Paid—————-135,405USD—-56,000,000USD
    Cash And Cash Equivalents Changes—————-3,458,839USD273,675USD-17,473,908USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductProduct Acetadote51,981USD0001087294-26-000049
    Q1 2026Quarterly · 2026-03-31ProductProduct Caldolor965,564USD0001087294-26-000049
    Q1 2026Quarterly · 2026-03-31ProductProduct Kristalose981,483USD0001087294-26-000049
    Q1 2026Quarterly · 2026-03-31ProductProduct Other168,850USD0001087294-26-000049
    Q1 2026Quarterly · 2026-03-31ProductProduct Sancuso2,928,634USD0001087294-26-000049
    Q1 2026Quarterly · 2026-03-31ProductProduct Talicia1,916,481USD0001087294-26-000049
    Q1 2026Quarterly · 2026-03-31ProductProduct Vibativ2,118,295USD0001087294-26-000049
    Q3 2025Quarterly · 2025-09-30ProductProduct Acetadote96,597USD0001087294-25-000020
    Q3 2025Quarterly · 2025-09-30ProductProduct Caldolor867,013USD0001087294-25-000020
    Q3 2025Quarterly · 2025-09-30ProductProduct Kristalose1,180,934USD0001087294-25-000020
    Q3 2025Quarterly · 2025-09-30ProductProduct Omeclamox Pak0USD0001087294-25-000020
    Q3 2025Quarterly · 2025-09-30ProductProduct Other306,510USD0001087294-25-000020
    Q3 2025Quarterly · 2025-09-30ProductProduct Sancuso3,240,947USD0001087294-25-000020
    Q3 2025Quarterly · 2025-09-30ProductProduct Vibativ2,598,454USD0001087294-25-000020
    Q2 2025Quarterly · 2025-06-30ProductProduct Acetadote193,546USD0001628280-25-039326
    Q2 2025Quarterly · 2025-06-30ProductProduct Caldolor1,588,293USD0001628280-25-039326
    Q2 2025Quarterly · 2025-06-30ProductProduct Kristalose2,754,299USD0001628280-25-039326
    Q2 2025Quarterly · 2025-06-30ProductProduct Omeclamox Pak0USD0001628280-25-039326
    Q2 2025Quarterly · 2025-06-30ProductProduct Other492,390USD0001628280-25-039326
    Q2 2025Quarterly · 2025-06-30ProductProduct Sancuso3,119,110USD0001628280-25-039326
    Q2 2025Quarterly · 2025-06-30ProductProduct Vibativ2,701,854USD0001628280-25-039326
    Q1 2025Quarterly · 2025-03-31ProductProduct Acetadote151,651USD0001087294-26-000049
    Q1 2025Quarterly · 2025-03-31ProductProduct Caldolor1,307,439USD0001087294-26-000049
    Q1 2025Quarterly · 2025-03-31ProductProduct Kristalose3,484,310USD0001087294-26-000049
    Q1 2025Quarterly · 2025-03-31ProductProduct Other3,141,629USD0001087294-26-000049
    Q1 2025Quarterly · 2025-03-31ProductProduct Sancuso2,256,294USD0001087294-26-000049
    Q1 2025Quarterly · 2025-03-31ProductProduct Talicia0USD0001087294-26-000049
    Q1 2025Quarterly · 2025-03-31ProductProduct Vibativ1,378,066USD0001087294-26-000049
    FY 2024Yearly · 2024-12-31ProductGrant400,000USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductOther930,241USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Acetadote185,182USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Caldolor4,959,385USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Kristalose15,315,259USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Omeclamox Pak-3,075USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Redi Trex90,237USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Sancuso9,005,129USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Talicia0USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Vaprisol-174,538USD0001087294-26-000020
    FY 2024Yearly · 2024-12-31ProductProduct Vibativ7,160,125USD0001087294-26-000020
    Q2 2024Quarterly · 2024-06-30ProductProduct Acetadote43,396USD0001628280-24-036529
    Q2 2024Quarterly · 2024-06-30ProductProduct Caldolor844,248USD0001628280-24-036529
    Q2 2024Quarterly · 2024-06-30ProductProduct Kristalose4,107,834USD0001628280-24-036529
    Q2 2024Quarterly · 2024-06-30ProductProduct Omeclamox Pak0USD0001628280-24-036529
    Q2 2024Quarterly · 2024-06-30ProductProduct Other213,792USD0001628280-24-036529
    Q2 2024Quarterly · 2024-06-30ProductProduct Sancuso2,188,776USD0001628280-24-036529
    Q2 2024Quarterly · 2024-06-30ProductProduct Vibativ2,454,481USD0001628280-24-036529
    Q1 2024Quarterly · 2024-03-31ProductGrant100,000USD0001628280-25-024342
    Q1 2024Quarterly · 2024-03-31ProductProduct Acetadote80,203USD0001628280-25-024342
    Q1 2024Quarterly · 2024-03-31ProductProduct Caldolor1,470,699USD0001628280-25-024342
    Q1 2024Quarterly · 2024-03-31ProductProduct Kristalose3,195,609USD0001628280-25-024342
    Q1 2024Quarterly · 2024-03-31ProductProduct Other275,329USD0001628280-25-024342
    Q1 2024Quarterly · 2024-03-31ProductProduct Sancuso1,827,769USD0001628280-25-024342
    Q1 2024Quarterly · 2024-03-31ProductProduct Vibativ1,605,489USD0001628280-25-024342
    FY 2023Yearly · 2023-12-31ProductManufactured Product Other2,039,015USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Acetadote458,759USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Caldolor4,333,923USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Kristalose15,981,850USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Omeclamox Pak20,030USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Redi Trex-341,886USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Sancuso8,096,788USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Vaprisol151,336USD0001628280-25-011366
    FY 2023Yearly · 2023-12-31ProductProduct Vibativ8,812,692USD0001628280-25-011366
    Q3 2023Quarterly · 2023-09-30ProductAcetadote120,052USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductCaldolor1,155,509USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductGrant100,000USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductKristalose3,887,476USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductOmeclamox Pak23,288USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductOther Products299,356USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductRedi Trex-122,556USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductSancuso1,933,222USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductVaprisol0USD0001628280-23-038418
    Q3 2023Quarterly · 2023-09-30ProductVIBATIV2,789,579USD0001628280-23-038418
    Q2 2023Quarterly · 2023-06-30ProductAcetadote150,163USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductCaldolor1,226,314USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductGrant60,000USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductKristalose4,110,718USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductOmeclamox Pak8,062USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductOther Products1,295,478USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductRedi Trex9,493USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductSancuso1,916,966USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductVaprisol23,857USD0001628280-23-029112
    Q2 2023Quarterly · 2023-06-30ProductVIBATIV2,147,826USD0001628280-23-029112
    FY 2022Yearly · 2022-12-31ProductGrant200,000USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductManufactured Product Other1,329,767USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Acetadote501,040USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Caldolor4,827,200USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Kristalose15,205,155USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Omeclamox Pak29,145USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Redi Trex-126,726USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Sancuso13,205,603USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Vaprisol-447,697USD0001628280-24-010725
    FY 2022Yearly · 2022-12-31ProductProduct Vibativ7,487,462USD0001628280-24-010725
    FY 2021Yearly · 2021-12-31ProductAcetadote850,993USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductCaldolor4,970,301USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductGrant400,000USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductKristalose15,993,658USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductOther151,127USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductProduct Vibativ11,704,062USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductRedi Trex55,321USD0001628280-23-007727
    FY 2021Yearly · 2021-12-31ProductSancuso0USD0001628280-23-007727

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.